EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis

Ning Xu iD, Linmu Chen, Lulu Liu, Wei Rong iD

PLOS ONE · 17.01.2023 · 18 (1) · e0278846

DOI: 10.1371/journal.pone.0278846 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS ONE, online erschienen am 17.01.2023. Verfasst von Ning Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Weihai Central Hospital affiliated to Qingdao University, Wendeng, Weihai, Shandong, People's Republic of China. Hauptthemen laut MEDLINE: Dexmedetomidine, Hypotension, Controlled. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This meta-analysis aimed to analyze and compare the efficacy and safety of remifentanil and dexmedetomidine applied respectively for controlled hypotension under general anesthesia. We searched the Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, SinoMed, Wanfang, and VIP databases, as well as dissertations and conference papers, to obtain randomized controlled trials comparing remifentanil and dexmedetomidine applied respectively for controlled hypotension before August 23, 2021. The primary outcomes included hemodynamic profiles, surgical field score, and blood loss. Extubation time, sedation and pain score at the PACU, and perioperative adverse events were the secondary outcomes. Nine randomized controlled trials with 543 patients (272 in the dexmedetomidine group and 271 in the remifentanil group) were eventually included. This meta-analysis indicated no significant difference between dexmedetomidine and remifentanil in terms of surgical field score, blood loss, minimum values of mean arterial pressure (MD 0.24 with 95% CI [-1.65, 2.13], P = 0.80, I 2 = 66%) and heart rate (MD 0.42 [-1.33, 2.17], P = 0.64, I 2 = 40%), sedation scores at the PACU (MD -0.09 [-0.69, 0.50], P = 0.76, I 2 = 92%), and incidence of bradycardia (OR 2.24 [0.70, 7.15], P = 0.17, I 2 = 0%). Compared with remifentanil, dexmedetomidine as the controlled hypotensive agent showed a lower visual analogue score at the PACU (MD -1.01 [-1.25, -0.77], P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineHypotension, ControlledHumansRemifentanilAnesthesia, GeneralNauseaVomiting

Substanzen

RemifentanilDexmedetomidine

Autor:innen und Institutionen

  • Department of Anesthesiology, Weihai Central Hospital affiliated to Qingdao University, Wendeng, Weihai, Shandong, People's Republic of China.
  • Department of Pain Medicine, Weihai Central Hospital affiliated to Qingdao University, Wendeng, Weihai, Shandong, People's Republic of China.
  • Department of Respiratory and Critical Care Medicine, Weihai Central Hospital affiliated to Qingdao University, Wendeng District, Weihai, Shandong, People's Republic of China.

ORCID-Profile: Ning Xu, Wei Rong

Zitieren

APA

Xu, N., Chen, L., Liu, L., & Rong, W. (2023). Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis. PLOS ONE, 18(1), e0278846. https://doi.org/10.1371/journal.pone.0278846

Vancouver

Xu N, Chen L, Liu L, Rong W. Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis. PLOS ONE. 2023;18(1):e0278846. doi:10.1371/journal.pone.0278846

BibTeX
@article{Xu2023,
  author = {Xu, Ning and Chen, Linmu and Liu, Lulu and Rong, Wei},
  title = {Dexmedetomidine versus remifentanil for controlled hypotension under general anesthesia: A systematic review and meta-analysis},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {1},
  pages = {e0278846},
  doi = {10.1371/journal.pone.0278846}
}
Kostenlos starten →